{"filings":[{"id":499049,"accession_number":"0001140361-26-021892","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2026-05-18T20:05:30+00:00","items":["5.03","9.01"],"status":"ready","headline":"Vericel amends bylaws to update address following headquarters move","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment effective May 18, 2026.","New principal executive offices: 25 Blue Sky Drive, Burlington, MA 01803.","Amendment is an administrative change; no other bylaw revisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99472,"accession_number":"0001628280-26-031713","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q1 revenue up 30% to $68.4M, net loss narrows; raises FY revenue guidance to $326-336M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue up 30% to $68.4M; MACI revenue up 22% to $56.4M, Burn Care up 91% to $12.0M.","Net loss narrowed to $6.3M from $11.2M; adjusted EBITDA up 195% to $9.6M (14% of revenue).","Raised full-year 2026 revenue guidance by $10M to $326-336M; reaffirmed ~75% gross margin and ~27% adjusted EBITDA margin.","Free cash flow of $15.1M; cash and investments $211M, no debt.","Received FDA approval for MACI commercial manufacturing at new facility; BARDA award up to $197M for NexoBrid."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":68425000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99471,"accession_number":"0001140361-26-018538","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Vericel shareholders elect all seven director nominees, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with votes ranging from 38.3M to 45.2M for; highest withhold 7.8M for Heidi Hagen.","Say-on-pay advisory proposal approved with 36.4M for, 9.7M against, 30.5K abstentions.","Ratification of PricewaterhouseCoopers as auditor for FY2026 approved with 45.0M for, 3.3M against, 21.9K abstentions.","Meeting held April 29, 2026; results filed May 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115496,"accession_number":"0001628280-26-012003","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q4 2025 total revenue $92.9M (+23% YoY); FY25 net income up 59% to $16.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $92.9M (+23% YoY); MACI revenue $84.1M (+23%); burn care $8.8M.","FY25 total revenue $276.3M (+16%); MACI revenue $239.5M (+21%); net income $16.5M ($0.32 diluted EPS).","Q4 adjusted EBITDA $37.3M (40% margin); FY25 adjusted EBITDA $70.9M (26% margin).","FY26 guidance: total revenue $316-326M, MACI revenue $280-286M, gross margin ~75%, adj. EBITDA margin ~27%.","Record Q4 MACI implants, biopsies, and implanting surgeons; MACI sales force expansion completed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":276259000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115495,"accession_number":"0001140361-26-001060","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vericel prelim 2025 revenue $276M (+23% Q4); MACI rev $239.5M; GAAP net profitable 2nd year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue ~$276M; MACI $239.5M (+20%+ YoY 3rd consecutive yr); Burn Care $36.5M.","Gross margin 74%; adj. EBITDA margin 26%; $200M cash & investments, no debt.","Q4 set records for MACI implants, implanting surgeons, biopsies; >900 MACI Arthro trained surgeons.","Completed sales force expansion; initiated MACI Ankle MASCOT trial; new mfg facility on track for 2026.","CEO cites strong execution, expects continued high revenue growth and profitability improvement in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":276259000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131921,"accession_number":"0001628280-25-049880","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel reports record Q3 revenue $67.5M; net income $5.1M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $67.5M (record Q3), MACI $55.7M (+25% YoY), Burn Care $11.8M (Epicel $10.4M, NexoBrid $1.5M).","Net income $5.1M ($0.10 diluted EPS) vs net loss $0.9M prior year; adjusted EBITDA $17.0M (25% rev) vs $10.0M (17%).","FY 2025 revenue guidance reaffirmed $272-276M; gross margin 74%, adjusted EBITDA margin 26%.","Operating cash flow $22.1M (record Q3); cash $185M, no debt; MACI Arthro >800 surgeons trained; MACI Ankle study on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":183341000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148493,"accession_number":"0001628280-25-036854","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q2 revenue $63.2M (+20% YoY); net loss narrows to $0.6M; adj. EBITDA up 112% to $13.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 total revenue $63.2M, up 20% YoY; MACI revenue $53.5M, up 21%.","Gross margin improved to 74% (vs 70% Q2 2024); non-GAAP adj. EBITDA $13.4M, 112% growth, margin 21%.","Net loss narrowed to $0.6M ($0.01/sh) from $4.7M loss ($0.10/sh) last year.","Cash & investments $164M, no debt; reaffirmed FY guidance: MACI revenue growth low 20s, gross margin 74%, adj. EBITDA margin 26%.","Received FDA IND clearance for Phase 3 MACI Ankle study; ~600 MACI Arthro surgeons trained."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":115838000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167320,"accession_number":"0001628280-25-023481","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel records Q1 MACI revenue $46.3M (+15% YoY), raises FY profitability guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 MACI revenue $46.3M (+15% YoY); total revenue $52.6M vs $51.3M YoY.","Net loss $11.2M ($0.23/diluted) vs $3.9M loss ($0.08) YoY; adjusted EBITDA $3.2M vs $7.2M.","Full-year revenue growth reaffirmed 20-23%; raised gross margin guidance to 74% and adjusted EBITDA margin to 26%.","~400 MACI Arthro surgeons trained; YTD biopsy growth >30% for trained surgeons; NexoBrid +207% YoY.","Cash $162M, no debt; tariffs expected negligible impact."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":52598000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167319,"accession_number":"0001140361-25-017110","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Vericel shareholders approve 5.09M share increase in 2022 Omnibus Incentive Plan and 2M share ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 5,088,095 share increase under Amended and Restated 2022 Omnibus Incentive Plan.","Shareholders approved 2,000,000 share increase under Amended and Restated 2015 Employee Stock Purchase Plan.","All seven director nominees elected with >96% votes in favor; abstentions/withheld minimal.","Advisory vote on executive compensation approved with about 88.7% of votes cast.","Ratification of PricewaterhouseCoopers LLP as auditor for fiscal 2025 approved with 96.1%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167318,"accession_number":"0001140361-25-013625","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vericel sees negligible impact from U.S. tariffs on COGS and gross margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All operations in U.S.; 100% of 2025 revenue from domestic sales.","Majority of manufacturing costs are fixed labor/overhead for MACI and Epicel.","Materials primarily from U.S. suppliers; imported material costs limited.","Maintains safety stock of NexoBrid and ACI-Maix collagen membrane.","Expects negligible impact on COGS and gross margin in 2025 and 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184646,"accession_number":"0001628280-25-008444","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel reports record Q4 gross margin 78%, FY2024 revenue up 20% to $237M, net income positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue $237.2M (+20% YoY); MACI $197.3M (+20%), Burn Care $39.9M (+22%).","Q4 GAAP net income $19.8M ($0.38 diluted EPS) vs $13.0M YoY; adjusted EBITDA margin 40%.","FY2024 adjusted EBITDA $53.4M (23% margin), up 58% YoY; operating cash flow $58.2M.","2025 guidance: revenue growth 20-23%, gross margin 73-74%, adj. EBITDA margin 25-26%.","MACI Arthro launch traction: ~250 surgeons trained; NexoBrid orders +42% QoQ; new facility on track."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":237224000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184645,"accession_number":"0001140361-25-001060","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vericel reports preliminary FY2024 revenue up 20% to ~$237M, adj EBITDA margin ~22%; Q4 MACI rev $68.2-68.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue ~$237-237.5M (+20% YoY); MACI revenue ~$197.2-197.7M (+20%); Burn Care $40M (+22%).","Q4 2024 MACI revenue $68.2-68.7M (+20-21% YoY, +53% QoQ); gross margin ~77%; net income ~$17.5-18.5M.","FY2024 adj EBITDA margin ~22%; Q4 adj EBITDA margin ~39%; cash & investments ~$167M, no debt.","2025 guidance: revenue growth 20-23%, gross margin 73-74%, adj EBITDA margin 25-26%.","Mid-term targets raised: gross margin high-70% range, adj EBITDA margin high-30% range by 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":237224000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201226,"accession_number":"0001628280-24-045997","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q3 revenue up 27% to $57.9M; raises full-year margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $57.9M (+27% YoY); MACI $44.7M (+19%), Burn Care $13.2M (+66%).","Gross margin 72% (+480bps YoY); net loss narrowed to $0.9M ($0.02/share) from $3.7M.","Adjusted EBITDA $10.0M (+84%, margin 17%); raised FY24 guidance: gross margin 72%, adj. EBITDA margin 22%.","FDA approved MACI Arthro for knee cartilage repair; NexoBrid pediatric indication also approved.","Cash $151M, no debt; operating cash flow $10.2M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":161848000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217247,"accession_number":"0001140361-24-038472","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Vericel's MACI Arthro for arthroscopic knee cartilage repair","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sBLA for arthroscopic delivery of MACI (MACI Arthro) to repair knee defects up to 4 cm².","MACI Arthro targets largest segment of $3B addressable market: ~20,000 patients/year with 2-4 cm² femoral condyle defects.","Vericel expanding target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic cartilage repair surgeons.","MACI is first FDA-approved cellularized scaffold and first restorative biologic approved for arthroscopic administration.","CEO Nick Colangelo: approval supports sustained top-tier revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217246,"accession_number":"0001140361-24-037511","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vericel's NexoBrid gets FDA approval for pediatric severe burn treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved NexoBrid for eschar removal in pediatric patients with deep partial- and full-thickness thermal burns.","Approval based on Phase 3 CIDS trial and additional pediatric data from earlier studies.","Target customer base expands to approximately 20 pediatric burn centers in the U.S.","NexoBrid was previously approved for adults in December 2022; pediatric indication adds new revenue opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217245,"accession_number":"0001628280-24-033894","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q2 revenue rises 15% to $52.7M; MACI up 21%; raises FY2024 margin guidance to 71%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["MACI net revenue $44.1M (+21% YoY); NexoBrid revenue $0.8M (+76% QoQ); Burn Care franchise total $8.5M.","Gross margin 70% (up 430bps); adjusted EBITDA $6.3M (+42%), margin 12% (up 230bps).","FY2024 guidance reaffirmed: revenue $238-242M; gross margin raised to 71%, adjusted EBITDA margin to 21%.","MACI Arthro launch expected later Q3 2024; NexoBrid pediatric FDA approval anticipated in Q3 2024.","Net loss $4.7M ($0.10 diluted EPS) vs $5.0M loss in prior year; cash $154M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":103943000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237044,"accession_number":"0001628280-24-021382","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q1 revenue up 25% to $51.3M; raises FY2024 guidance to $238-242M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["MACI revenue grew 18% to $40.2M; Burn Care revenue up 63% to $11.1M (Epicel $10.7M, NexoBrid $0.4M).","Net loss narrowed to $3.9M ($0.08/shr) from $7.5M; adjusted EBITDA surged 325% to $7.2M (14% margin).","Gross margin improved ~400bps to 69%; FY2024 revenue guidance raised to $238-242M (from $237-241M).","Over 60 NexoBrid P&T submissions, ~40 burn centers approved; no debt and $148M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":51281000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237043,"accession_number":"0001140361-24-024327","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Vericel shareholders elect all eight director nominees and approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected with 35.2M to 42.3M votes each; Robert Zerbe received 41.3M for.","Advisory say-on-pay approved with 41.2M for, 2.0M against, 36.6K abstain.","Shareholders voted for annual say-on-pay frequency (42.5M for 1 year); board adopted yearly vote.","Ratification of PricewaterhouseCoopers as auditor approved with 43.6M for, 1.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254634,"accession_number":"0001628280-24-007807","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel reports FY2023 revenue $197.5M (+20% YoY); Q4 revenue $65.0M; FY2024 guidance $237-241M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $13.0M ($0.26 diluted EPS) vs $5.9M in Q4 2022, up 119%.","FY2023 net loss narrowed to $3.2M from $16.7M; adjusted EBITDA $33.9M (+40%).","MACI net revenue grew 22% to $56.7M in Q4; Burn Care revenue up 31% to $8.3M.","FY2024 total revenue guidance $237-241M; gross margin ~70%; adj. EBITDA margin ~20%.","Cash and investments $152.6M, zero debt; MACI arthroscopic delivery submission accepted by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":197516000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254633,"accession_number":"0001140361-24-001518","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vericel reports preliminary FY2023 revenue ~$197.5M (+20% YoY); Q4 revenue $65M (+23%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 preliminary total revenue ~$197.5M (+20% YoY); MACI revenue ~$164.8M (+25%); Burn Care revenue ~$32.7M.","Q4 2023 revenue ~$65M (+23% YoY); MACI $56.7M (+22%); Burn Care $8.3M (+31%); gross margin >70%.","Record-high Q4 MACI implants, implanting surgeons, biopsies, and biopsies since launch; highest Epicel biopsies since 2021.","Cash, restricted cash & investments ~$152M, no debt; adjusted EBITDA margin ~30% in Q4, mid-teens for full year.","NexoBrid U.S. launch underway with >50 burn centers submitted to P&T committees; arthroscopic MACI launch expected later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":197516000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272101,"accession_number":"0001628280-23-037567","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel reports Q3 2023 revenue of $45.6M (+18% YoY), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $45.6M (+18% YoY); MACI revenue $37.6M (+21% YoY).","Net loss $3.7M ($0.08/sh); adjusted EBITDA $5.4M (12% of revenue).","FY2023 revenue guidance raised to $192.5-197.5M from prior $190-197M.","Cash $149M, no debt; 13th consecutive quarter of positive adjusted EBITDA and operating cash flow.","MACI arthroscopic delivery launch expected H1 2024; NexoBrid commercially launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":132520000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288947,"accession_number":"0001104659-23-102314","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vericel launches NexoBrid in U.S. for severe thermal burns; $300M addressable market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full commercial launch of NexoBrid for eschar removal in adults with deep partial/full-thickness thermal burns.","Selective enzymatic debridement preserves viable tissue vs. surgical excision.","Addressable U.S. market of ~30,000 patients/year, equating to $300 million.","Product can be applied in up to two 4-hour sessions covering up to 20% total body surface area.","Launch expands Vericel's Burn Care franchise and diversifies revenue stream."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288946,"accession_number":"0001628280-23-026579","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q2 revenue $45.9M (+24% YoY); raises FY2023 guidance to $190-197M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $45.9M (+24% YoY); MACI $36.3M (+27%), Epicel $9.6M (+17%).","Net loss $5.0M ($0.11 EPS) improved from $9.0M loss in Q2 2022; adjusted EBITDA $4.4M.","Full-year 2023 revenue guidance raised to $190-197M from prior $184-192M; gross margin guidance high-60% maintained.","MACI arthroscopic delivery program on track for 2024 commercial launch; human factors study planned Q3.","Extended exclusive supply agreement with Matricel GmbH for MACI collagen membrane."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":86939000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309649,"accession_number":"0001628280-23-017028","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel reports record Q1 2023 revenue of $41M; MACI up 32%; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $41.0M (+14% YoY); MACI revenue $34.2M (+32% YoY); Epicel $6.8M.","Net loss $7.5M ($0.16/diluted share) vs $7.1M loss a year ago; adjusted EBITDA $1.7M (4% rev).","Full-year 2023 revenue guidance raised to $184-$192M from prior $180-$188M; maintains margin guidance.","Cash and investments $139M, no debt; operating cash flow of $7.9M.","MACI arthroscopic delivery program on track for 2024 commercial launch; NexoBrid P&T approvals ahead of goals."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":41017000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309648,"accession_number":"0001140361-23-023201","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Vericel adopts deferred comp plan; shareholders reelect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Vericel Corporation Deferred Compensation Plan effective May 3, 2023.","Plan allows Directors and select management to defer up to 100% of base salary, bonus, cash director fees, and RSUs.","All eight director nominees elected with votes ranging from 35.4M to 40.2M in favor.","Non-binding advisory vote on executive compensation approved: 38.4M for, 3.2M against, 150K abstentions.","Ratification of PwC as independent auditor for FY2023 approved: 42.4M for, 1.8M against, 205K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328367,"accession_number":"0001628280-23-004701","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q4 revenue $52.7M record; net income up 31%; 2023 guidance $180-188M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $52.7M (+11% YoY); MACI revenue $46.3M (+24% YoY); Epicel $6.3M.","Q4 net income $5.9M ($0.12 diluted) vs $4.5M ($0.09) a year ago; adjusted EBITDA $14.9M (28% margin).","Full-year 2022 total revenue $164.4M; net loss $16.7M ($0.35 diluted); adjusted EBITDA $24.2M (15% margin).","2023 guidance: total revenue $180-188M, MACI $152-156M, burn care $28-32M, gross margin high-60%.","FDA approved NexoBrid for eschar removal; U.S. commercial launch expected Q2 2023; arthroscopic MACI on track for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":164365000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328366,"accession_number":"0001104659-23-002721","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vericel prelim FY2022 rev ~$164-165M; MACI arthro launch accelerated to 2024; NexoBrid approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2022 total revenue expected ~$164-165M; MACI rev ~$132M at high end of guidance.","Q4 MACI revenue growth ~24% YoY; 10th straight quarter of positive adjusted EBITDA and operating cash flow.","Cash and investments ~$140M, no debt as of Dec 31, 2022.","NexoBrid FDA approved Dec 28, 2022 for eschar removal in thermal burns; U.S. commercial launch expected Q2 2023.","MACI arthroscopic delivery human factors study planned for 2023; commercial launch now expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346018,"accession_number":"0001104659-22-130934","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vericel gets FDA approval for NexoBrid to treat severe thermal burns in adults","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved NexoBrid (anacaulase-bcdb) for eschar removal in adults with deep partial- and full-thickness thermal burns.","Approval based on Phase 3 DETECT study meeting primary endpoint of complete eschar removal vs placebo.","NexoBrid showed shorter time to eschar removal and lower incidence of surgical removal vs standard of care.","Commercial launch expected in Q2 2023; company plans to establish it as new standard of care.","Expands Vericel's target addressable market beyond sports medicine into severe burn care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346017,"accession_number":"0001628280-22-029065","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q3 revenue $38.6M (+12% YoY); MACI $31M (+30%); net loss $6.6M; FY22 guidance $164-166M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $38.6M (+12% YoY); MACI net revenue $31.0M (+30% YoY); Epicel $7.3M; NexoBrid $0.2M.","Net loss of $6.6M ($0.14 per share) vs $4.9M loss in Q3 2021; adjusted EBITDA $3.3M.","Full-year 2022 guidance: total revenue $164-166M, MACI $130-132M, burn care ~$34M, gross margin mid-60%.","Cash and investments $133M, no debt; ninth straight quarter of positive adjusted EBITDA and operating cash flow.","NexoBrid BLA review progressing with FDA inspections; Type C meeting scheduled for MACI arthroscopic delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":111671000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362426,"accession_number":"0001628280-22-020345","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q2 revenue $37M, net loss $9M; maintains FY guidance, NexoBrid BLA accepted with PDUFA Jan 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $37.0M (MACI $28.6M +8% YoY, Epicel $8.2M, NexoBrid $0.2M); net loss $9.0M ($0.19/sh).","Non-GAAP adjusted EBITDA $2.8M (7% margin); operating cash flow $3.1M; cash & investments $131M, no debt.","FY 2022 guidance reaffirmed: total revenue $178-189M, MACI $132-141M, gross margin ~69%, adj. EBITDA margin ~21%.","NexoBrid BLA resubmission accepted by FDA; PDUFA date Jan 1, 2023.","Entered $150M revolving credit facility with J.P. Morgan-led syndicate; issued inaugural ESG report."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":73120000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362425,"accession_number":"0001104659-22-085173","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Vericel enters $150M senior secured revolving credit facility due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$150 million five-year senior secured revolver; matures July 29, 2027.","Facility secured by first-priority lien on substantially all assets; includes $5M swingline and $15M letter of credit sub-facility.","Interest rate options: SOFR + 0.10% plus spread 1.25%-2.50%, or base rate plus 0.25%-1.50%.","Proceeds for general corporate purposes, including acquisitions and capex.","Commitment fee 0.20%-0.25%; financial covenants including max total net leverage ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381985,"accession_number":"0001628280-22-012148","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q1 revenue up 4% to $36.1M; net loss widens to $7.1M; reaffirms FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $36.1M (+4% YoY); MACI $26.0M, Epicel $9.9M, NexoBrid $0.2M.","Net loss $7.1M ($0.15/share) vs $3.3M loss a year ago; non-GAAP adj. EBITDA $3.2M.","Reaffirmed FY2022 guidance: revenue $178-189M, gross margin ~70%, adj. EBITDA margin ~21%.","MACI and Epicel biopsies growing double-digit; NexoBrid BLA resubmission on track for mid-2022.","Appointed Mike Gilligan as VP, MACI National Sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":36074000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381984,"accession_number":"0001104659-22-053666","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Vericel shareholders approve 2022 Omnibus Incentive Plan, re-elect all directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected 8 directors: Zerbe, Rubino, Hagen, Gilman, McLaughlin, Wotton, Wright, Colangelo (each >35M votes for).","Approved 2022 Omnibus Incentive Plan reserving 5,572,710 shares for future equity awards.","Non-binding advisory vote on executive compensation passed (34.8M for, 5.5M against).","Ratified PwC as independent auditor for FY2022 (42.0M for, 1.1M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399944,"accession_number":"0001628280-22-003659","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel FY2021 revenue $156.2M (+26% YoY); net loss $7.5M; guides FY2022 revenue $178-189M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 total net revenue $156.2M (up 26% YoY); MACI $111.6M, Epicel $41.5M.","FY2021 net loss $7.5M ($0.16/share) vs net income $2.9M ($0.06/share) in 2020.","Non-GAAP adjusted EBITDA $29.5M (19% margin), up from $18.6M (15%) in 2020.","FY2022 guidance: revenue $178-189M; MACI $132-141M, Epicel $45.5-47.5M; gross margin ~70%, adj EBITDA ~21%.","Cash and investments $129M as of Dec 31, 2021; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":156184000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399943,"accession_number":"0001104659-22-026723","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vericel appoints Jonathan Siegal as Principal Accounting Officer effective Feb 16","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Siegal, VP and Corporate Controller, appointed principal accounting officer effective Feb 16, 2022.","Siegal replaces Joseph Mara, who will remain CFO and principal financial officer.","Siegal joined Vericel in Sep 2021; previously Global Controller at Lantheus Medical Imaging.","No new compensatory arrangements, family relationships, or transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399942,"accession_number":"0001104659-22-010829","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Vericel signs 125,749 sq ft lease for Burlington, MA HQ and manufacturing facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed 144-month lease with one 120-month extension option for to-be-constructed manufacturing, lab, and office space.","Annual base rent starts at $57/sq ft with 2.5% annual escalations; landlord provides ~$25.1M tenant improvement allowance.","Construction core and shell expected to start Feb 28, 2023; rent begins 13 months later or when Vericel first occupies.","Delivered ~$6.0M letter of credit as security deposit, reducing to ~$4.2M after year 3 and ~$1.8M after year 6.","No material relationship with landlord; facility will serve as new corporate headquarters and primary manufacturing site."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399941,"accession_number":"0001104659-22-003394","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vericel estimates FY2021 revenue growth 25-26%, adj. EBITDA ~$30M, cash ~$129M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2021 revenue growth of 25%-26% (unaudited); total adjusted EBITDA ~$30M.","Cash and investments as of Dec 31, 2021 ~$129M.","Company presented at 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.","Financial results are preliminary and subject to change upon audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":156184000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418904,"accession_number":"0001628280-21-022408","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q3 revenue up 7% to $34.5M; guides FY2021 revenue $158-$161M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total net revenue $34.5M (+7% YoY); MACI $23.9M, Epicel $9.8M (+48% YoY).","Q3 net loss $4.9M ($0.11/sh) vs net income $3.6M in Q3 2020; non-GAAP adj. EBITDA $4.3M.","FY2021 guidance: revenue $158-$161M (27-30% YoY growth); gross margin ~70%; adj. EBITDA margin ~22%.","Cash and investments $119M, no debt; operating cash flow $3.6M in Q3.","NexoBrid BLA resubmission expected mid-2022; MACI biopsies growth >30% expected in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":108593000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436494,"accession_number":"0001104659-21-110616","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vericel enters ATM equity offering agreement for up to $200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with SVB Leerink LLC to sell up to $200M of common stock in at-the-market offerings.","Sales may be made via ordinary brokers' transactions at prevailing market prices on Nasdaq.","SVB Leerink receives 3.0% commission on gross proceeds from sold shares.","Company is not obligated to sell any shares; can suspend or terminate offering on notice.","Prospectus supplement filed August 27, 2021; shelf registration on Form S-3ASR effective same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436493,"accession_number":"0001628280-21-015447","cik":887359,"company_name":"Vericel Corp","ticker":"VCEL","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vericel Q2 revenue up 97% to $39.5M; raises FY2021 revenue guidance to $168-171M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $39.5M (+97% YoY); MACI $26.5M, Epicel $12.2M, NexoBrid $0.8M.","Net loss narrowed to $3.8M ($0.08/sh) from $8.3M loss; non-GAAP adjusted EBITDA $7.8M (20% margin).","Full-year 2021 revenue guidance raised to $168-171M; adjusted EBITDA margin guided to 23%-25%.","Record quarterly MACI biopsies and Epicel grafting; MACI biopsies up >50% in H1 2021 vs H1 2020.","Cash and investments $116M, no debt; operating cash flow $4.8M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":74087000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1761340000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}